CSTL ▼ -0.1% - Castle Biosciences, Inc. $CSTL New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus 28-SEP-2026 07:00 AM ET